Pharmacogenetics of quetiapine

Abdyrakhmanova, A. K.; Shnayder, N. А.; Незнанов, Н. Г.; Насырова, Р. Ф.

doi:10.52667/2712-9179-2021-1-1-73-83

Cited by 4 publications

(5 citation statements)

References 26 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, when predicting the development of AIP, one should take into account not only the risk factors, but also protective factors of AIP: taking anticholinergic drugs (due to increased cholinergic activity, which leads to stimulation of the GABA-ergic inhibitory pathway in the basal ganglia); smoking (nicotine can act as an inhibitor of monoamine oxidase B, increasing the availability of dopamine) [ 28 ]. In recent decades, genetic predictors of AIP and AP-induced TD have been actively studied as a risk for the development of these neurological ADRs [ 120 , 121 , 122 ].…”

Section: Discussionmentioning

confidence: 99%

Pathophysiological Mechanisms of Antipsychotic-Induced Parkinsonism

et al. 2022

View full text Add to dashboard Cite

Among neurological adverse reactions in patients with schizophrenia treated with antipsychotics (APs), drug-induced parkinsonism (DIP) is the most common motility disorder caused by drugs affecting dopamine receptors. One of the causes of DIP is the disruption of neurotransmitter interactions that regulate the signaling pathways of the dopaminergic, cholinergic, GABAergic, adenosinergic, endocannabinoid, and other neurotransmitter systems. Presently, the development mechanisms remain poorly understood despite the presence of the considered theories of DIP pathogenesis.

show abstract

Section: Discussionmentioning

confidence: 99%

Pathophysiological Mechanisms of Antipsychotic-Induced Parkinsonism

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In different people, the set of the cytochrome P450 isoenzymes in the endoplasmic reticulum (ER) and on the inner mitochondrial membrane differs due to genetic characteristics. In this regard, the study of genetically determined changes in the expression of the functional activity of CYP family isoenzymes is of great clinical importance in psychiatry and clinical pharmacology [2][3][4][5][6][7][8][9][10].…”

Section: Discussionmentioning

confidence: 99%

“…For the treatment of mental disorders, including BPs, psychotropic drugs (PDs) are usually used, in particular, antipsychotics (APs) and drugs with normothymic action [1]. The problem of PD-induced adverse drug reactions (ADRs) has not been solved yet, and the accumulated experience in targeted prevention of PD-induced ADRs suggests that most of them can be prevented or their consequences can be significantly reduced [2][3][4][5].…”

Section: Introductionmentioning

confidence: 99%

Pharmacogenetic Testing of Cytochrome P450 System Enzymes in the Therapy of Bipolar Affective Disorder

Khasanova

Насырова

2022

jour

Self Cite

View full text Add to dashboard Cite

Bipolar affective disorder (BPS) is a common and socially significant mental disorder that requires long-term use of psychotropic drugs (PDs). Long-term use of PDs increases the risk of developing adverse drug reactions (ADRs) and/or therapeutic resistance in some patients. This may be due to a genetically determined impairment of PDs metabolism by cytochrome P450 enzymes. Pharmacogenetic testing (PGx) is a method to identify a group of patients with a high risk of developing PDs -induced ADRs. Our experience of using PGx to search for low-functional and non-functional single nucleotide variants (SNVs) / polymorphisms of the CYP1A2, CYP2C8, CYP3A4, CYP3A5 and CYP2D6 genes encoding cytochrome P450 enzymes involved in PDs metabolism demonstrates the importance of this new personalized approach to the choice of PDs and its dosing in patients with pharmacogenetic profile poor metabolizer. The main purpose of the case report is to present the experience of using PGx in the therapy of dipolar affective disorder.

show abstract

“…Individual enzymes of this system are involved in the biotransformation of certain APs, with a unique substrate specificity. This specificity may partially coincide in different enzymes of the CYP system (Table 1) [29]. Currently, at least 50 different P450 enzymes are known, but approximately 12 of them provide biotransformation of most APs.…”

Section: Oxidation Of Antipsychotics In the Livermentioning

confidence: 99%

Oxidation of Antipsychotics

2022

View full text Add to dashboard Cite

Antipsychotics (APs) are psychotropic drugs that generally have a psycholeptic effect, capable of reducing psychotic symptoms and psychomotor agitation. This class of drugs is widely used in psychiatric practice, especially for the treatment of psychosis in schizophrenia and other psychotic disorders. Most APs pass through a biotransformation process, or metabolism, after they enter the body before being eliminated. There are three phases of AP metabolism. Cytochrome P450 (CYP) monooxygenase (mixed-function oxidase) plays a central role in most AP biotransformation. CYP’s functional activity depends on gene–drug and drug–drug interaction and influences on the occurrence of adverse drug reactions (ADRs). So, it is extremely important for a practicing psychiatrist to know the oxidation pathway of APs, since most of them are metabolized in the liver. This is important both to prevent ADRs and to avoid unwanted drug–drug interactions, which will undoubtedly increase the effectiveness and safety of AP therapy.

show abstract

Pharmacogenetics of quetiapine

Cited by 4 publications

References 26 publications

Pathophysiological Mechanisms of Antipsychotic-Induced Parkinsonism

Pathophysiological Mechanisms of Antipsychotic-Induced Parkinsonism

Pharmacogenetic Testing of Cytochrome P450 System Enzymes in the Therapy of Bipolar Affective Disorder

Oxidation of Antipsychotics

Contact Info

Product

Resources

About